Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2020

View Archived Issues

A20's inflammation-fighting properties decoded

Discovery and preclinical evaluation of an oral nicotinic acetylcholine alpha7 receptor PAM

Discovery of ketone-linked benzimidazole-benzoxaborole hybrids for the treatment of onchocerciasis

JAM2 is recurrently mutated in families with recessive primary familial brain calcification

Capricor initiates compassionate use program for patients with severe COVID-19

Futura Medical presents further detailed data from FM57 phase III study of MED-3000

Horizon Therapeutics acquires LPA1 receptor antagonist for dcSSc

Positive interim data from phase IIb study of UGN-102

Mouse model of COPD established through use of intratracheal spray

Novel diet-induced obese rat model of AF

Optogenetic plaque model traces neurodegeneration in AD

Microbiome changes precede tumor development in CRC

Collaboration between UW-Madison, FluGen and Bharat Biotech to develop COVID-19 vaccine

Ivermectin, approved as an antiparasitic, inhibits SARS-CoV-2 in vitro

Inositec patents calcium oxalate crystallization inhibitors

Aprea Therapeutics divulges quinuclidine derivatives for cancer

Chinese investigators identify new TLR8 agonists

ViiV Healthcare presents compounds for HIV infection

New HER2 inhibitors identified by Suzhou Zanrong Pharma

SHR-1701 begins new phase I trials for advanced solid tumors and nasopharyngeal carcinoma

European Commission approves Rybelsus for type 2 diabetes

Union Therapeutics announces program with optimized salt form of niclosamide to treat COVID-19

FDA approves Reblozyl to treat anemia in MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...